| scholarly article | Q13442814 |
| editorial | Q871232 |
| P2093 | author name string | Sanjay Kalra | |
| Nor Azmi Kamaruddin | |||
| Ravi Santani | |||
| Jayanti Visvanathan | |||
| P2860 | cites work | AACE/ACE comprehensive diabetes management algorithm 2015. | Q50931076 |
| UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. | Q51570043 | ||
| Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high | Q52655639 | ||
| Anti-diabetic medications: How to make a choice? | Q53601871 | ||
| Salutogenesis in Type 2 Diabetes Care: A Biopsychosocial Perspective. | Q55357283 | ||
| Beta-cell Insufficiency | Q88312469 | ||
| Progression from newly acquired impaired fasting glusose to type 2 diabetes | Q24683882 | ||
| Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research | Q26782844 | ||
| Current perspectives on cardiovascular outcome trials in diabetes | Q28066006 | ||
| Regulatory scientific advice on non-inferiority drug trials | Q28536760 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| Defining and characterizing the progression of type 2 diabetes | Q33610728 | ||
| beta-Cell death during progression to diabetes | Q34462324 | ||
| Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial | Q34516303 | ||
| Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC | Q35004314 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%. | Q37312900 | ||
| A review of the efficacy and safety of oral antidiabetic drugs | Q38067491 | ||
| Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials | Q38219234 | ||
| Key pathways in renal disease progression of experimental diabetes | Q38553926 | ||
| Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment | Q38615808 | ||
| Understanding the nature of renal disease progression | Q41314057 | ||
| The dirty dozen of diabetes | Q41858733 | ||
| Coefficient of failure: a methodology for examining longitudinal beta-cell function in Type 2 diabetes | Q44024462 | ||
| Global aetiology and epidemiology of type 2 diabetes mellitus and its complications | Q45305959 | ||
| Pentads and Hexads in Diabetes Care: Numbers as Targets; Numbers as Tools | Q47122631 | ||
| C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. | Q47299422 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 67-69 | |
| P577 | publication date | 2019-08-16 | |
| P1476 | title | Defining Disease Progression and Drug Durability in Type 2 Diabetes Mellitus | |
| P478 | volume | 15 |
Search more.